Adverum Biotechnologies Valuation
| ADVM Stock | USD 6.64 0.19 2.95% |
At this time, the firm appears to be overvalued. Adverum Biotechnologies shows a prevailing Real Value of $5.12 per share. The current price of the firm is $6.64. Our model approximates the value of Adverum Biotechnologies from analyzing the firm fundamentals such as Return On Equity of -0.76, operating margin of (29.22) %, and Shares Outstanding of 20.8 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Adverum Biotechnologies' valuation include:
Price Book 0.9585 | Enterprise Value 58.2 M | Enterprise Value Ebitda 0.099 | Price Sales 138.1286 | Enterprise Value Revenue 58.1504 |
Overvalued
Today
Please note that Adverum Biotechnologies' price fluctuation is moderately volatile at this time. Calculation of the real value of Adverum Biotechnologies is based on 3 months time horizon. Increasing Adverum Biotechnologies' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Adverum stock is determined by what a typical buyer is willing to pay for full or partial control of Adverum Biotechnologies. Since Adverum Biotechnologies is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Adverum Stock. However, Adverum Biotechnologies' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.64 | Real 5.12 | Target 4.25 | Hype 6.64 | Naive 6.85 |
The intrinsic value of Adverum Biotechnologies' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Adverum Biotechnologies' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Adverum Biotechnologies helps investors to forecast how Adverum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Adverum Biotechnologies more accurately as focusing exclusively on Adverum Biotechnologies' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Adverum Biotechnologies' intrinsic value based on its ongoing forecasts of Adverum Biotechnologies' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Adverum Biotechnologies' closest peers.
Adverum Biotechnologies Cash |
|
Adverum Valuation Trend
Knowing Adverum Biotechnologies' actual value is paramount for traders when making sound investment determinations. Using both Adverum Biotechnologies' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Adverum Biotechnologies Total Value Analysis
Adverum Biotechnologies is presently anticipated to have valuation of 58.15 M with market capitalization of 138.13 M, debt of 75.04 M, and cash on hands of 235.84 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Adverum Biotechnologies fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
58.15 M | 138.13 M | 75.04 M | 235.84 M |
Adverum Biotechnologies Investor Information
About 79.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.96. Some equities with similar Price to Book (P/B) outperform the market in the long run. Adverum Biotechnologies recorded a loss per share of 5.95. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 21st of March 2024. Based on the key indicators related to Adverum Biotechnologies' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Adverum Biotechnologies is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Adverum Biotechnologies Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Adverum Biotechnologies has an asset utilization ratio of 2.08 percent. This suggests that the Company is making $0.0208 for each dollar of assets. An increasing asset utilization means that Adverum Biotechnologies is more efficient with each dollar of assets it utilizes for everyday operations.Adverum Biotechnologies Ownership Allocation
Adverum Biotechnologies holds a total of 20.8 Million outstanding shares. The majority of Adverum Biotechnologies outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Adverum Biotechnologies to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Adverum Biotechnologies. Please pay attention to any change in the institutional holdings of Adverum Biotechnologies as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Adverum Biotechnologies Profitability Analysis
The company reported the previous year's revenue of 3.6 M. Net Loss for the year was (117.17 M) with loss before overhead, payroll, taxes, and interest of (81.68 M).About Adverum Biotechnologies Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Adverum Biotechnologies. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Adverum Biotechnologies based exclusively on its fundamental and basic technical indicators. By analyzing Adverum Biotechnologies's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Adverum Biotechnologies's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Adverum Biotechnologies. We calculate exposure to Adverum Biotechnologies's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Adverum Biotechnologies's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2 M | -1.9 M | |
| Pretax Profit Margin | (37.77) | (39.66) | |
| Operating Profit Margin | (39.54) | (41.52) | |
| Net Loss | (37.43) | (39.30) | |
| Gross Profit Margin | (0.65) | (0.62) |
Adverum Biotechnologies Growth Indicators
Investing in growth stocks can be very risky. If the company such as Adverum Biotechnologies does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 10.1 M |
Adverum Biotechnologies Current Valuation Indicators
Adverum Biotechnologies' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Adverum Biotechnologies' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Adverum Biotechnologies, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Adverum Biotechnologies' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Adverum Biotechnologies' worth.When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.